Navigation Links
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly form of brain cancer.

In pilot studies Cotara has shown encouraging results, demonstrating a 58% increase in the expected median survival time in a group of 28 patients suffering from recurrent late stage glioblastoma multiforme. This was considered a promising development in this serious and deadly disease, which kills half of its victims within 14 months of diagnosis.

Peregrine believes that combined positive data from this new study in India and ongoing U.S. glioblastoma trials would provide a foundation for advancing Cotara into Phase III trials.

"Cotara has demonstrated promising increases in survival in previous clinical studies of late stage glioblastoma patients, and we are optimistic that the very large population of glioblastoma patients served by our Indian study centers will facilitate timely enrollment in this important new trial," said Steven W. King, president and CEO of Peregrine. "We anticipate that positive data from this study, together with dosimetry and dosing data being collected in ongoing U.S. Cotara trials, will help us determine the optimal design of Phase III product registration trials."

This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study's primary objective is to confirm the maximum tolerated dose of Cotara in patients with GBM at first relapse.

Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patien ts alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), an NIH-developed technique that delivers the agent to the tumor with great precision, achieving up to a 10,000-fold greater concentration in local therapy exposure than conventional intravenous drug administration, while minimizing unwanted exposure to healthy tissue. This delivery method is expected to further enhance the tumor-killing efficacy of Cotara.

Mr. King continued, "We are launching this Cotara clinical program in India to take advantage of the large population of GBM patients served by our study centers and the high level of experience with CED delivery of the participating neurosurgeons, as well as the fact that the contract research organization overseeing the trial is highly experienced in conducting similar glioblastoma trials with many of the investigators involved with our study."

The new Cotara study is being conducted according to internationally accepted ICH GCP guidelines.


'"/>




Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
5. Top Pharmaceuticals Influence Doctors Prescriptions
6. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
7. Personalized Medicine and Innovative Pharmaceuticals
8. Pravastatin Launched by Watson Pharmaceuticals
9. Tata Industries picks up stake in Indigene Pharmaceuticals
10. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
11. OPPI Opposes Draft National Pharmaceuticals Policy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding them ... a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to provide ... need to turn on a light when taking medication during the night, allowing the ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: